Arbutus Biopharma Corporation (ABUS) Earnings History
Profitable28 years of earnings data (1998–2025) · Positive TTM net income
Loading earnings history...
Arbutus Biopharma Corporation (ABUS) Earnings Overview
As of June 29, 2026, Arbutus Biopharma Corporation (ABUS) reported trailing twelve-month net income of $161M, reflecting +55.3% year-over-year growth. The company earned $0.82 per diluted share over the past four quarters, with a net profit margin of -237.9%.
Looking at the long-term picture, ABUS's historical earnings data spans multiple years. The company achieved its highest annual net income of $30M in fiscal 2012.
Arbutus Biopharma Corporation maintains positive profitability with a gross margin of 97.4%, operating margin of -192.1%, and net margin of -237.9%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including REPL (-$315M net income), ASMB (-$6M net income, -8.5% margin), HBIO (-$10M net income, -65.5% margin), ABUS has comparable earnings metrics. Compare ABUS vs REPL →
ABUS Earnings vs Peers
Earnings metrics vs comparable public companies
ABUS Historical Earnings Data (1998–2025)
28 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$34M | +52.1% | -$27M | $-0.17 | -237.9% | -192.1% |
| 2024 | -$70M | +4.0% | -$76M | $-0.38 | -1133.0% | -1236.7% |
| 2023 | -$73M | -4.9% | -$78M | $-0.44 | -401.6% | -430.5% |
| 2022 | -$69M | +8.9% | -$65M | $-0.46 | -178.0% | -167.8% |
| 2021 | -$76M | -19.6% | -$74M | $-0.73 | -693.9% | -669.1% |
| 2020 | -$64M | +58.5% | -$58M | $-0.86 | -922.0% | -836.1% |
| 2019 | -$154M | -169.2% | -$144M | $-2.69 | -2557.4% | -2394.0% |
| 2018 | -$57M | +32.3% | -$90M | $-1.03 | -967.8% | -1522.0% |
| 2017 | -$84M | +78.0% | -$111M | $-1.54 | -788.8% | -1036.4% |
| 2016 | -$384M | -528.4% | -$492M | $-7.24 | -25606.7% | -32773.3% |
| 2015 | -$61M | -57.5% | -$102M | $-1.34 | -245.7% | -411.4% |
| 2014 | -$39M | -175.9% | -$33M | $-1.73 | -258.7% | -220.0% |
| 2013 | -$14M | -147.0% | -$12M | $-0.92 | -90.9% | -78.6% |
| 2012 | $30M | +407.7% | -$13M | $2.07 | 211.2% | -91.6% |
| 2011 | -$10M | +21.6% | -$10M | $-0.86 | -59.7% | -63.3% |
| 2010 | -$12M | -33.1% | -$13M | $-1.20 | -58.1% | -58.6% |
| 2009 | -$9M | +20.4% | -$9M | $-0.90 | -67.7% | -65.8% |
| 2008 | -$12M | -353.7% | -$11M | $-1.44 | -121.6% | -113.6% |
| 2007 | -$3M | -114.3% | $3M | $-0.54 | -16.2% | 16.6% |
| 2006 | $18M | +324.3% | -$2M | $4.68 | 132.9% | -12.4% |
| 2005 | -$8M | +71.3% | -$6M | $-1.04 | -60.6% | -44.8% |
| 2004 | -$28M | +17.7% | -$28M | $-3.64 | -230.5% | -227.1% |
| 2003 | -$34M | -27.2% | -$35M | $-4.78 | -1247.3% | -1268.1% |
| 2002 | -$27M | -91.2% | -$28M | $-4.08 | -528.3% | -546.5% |
| 2001 | -$14M | -52.3% | -$16M | $-2.76 | -405.1% | -474.4% |
| 2000 | -$9M | -12.6% | -$9M | $-1.87 | -520.6% | -520.6% |
| 1999 | -$8M | +6.6% | -$8M | $-2.90 | -716.7% | -716.7% |
| 1998 | -$9M | - | -$9M | $-4.05 | -713.2% | -713.2% |
Download Data
Export ABUS earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
28+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ABUS — Frequently Asked Questions
Quick answers to the most common questions about buying ABUS stock.
What is ABUS earnings per share (EPS)?
ABUS trailing twelve-month (TTM) diluted EPS is $0.82, reflecting +55.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1998 to 2025 is available in the table on this page.
What is Arbutus Biopharma Corporation's net income?
Arbutus Biopharma Corporation (ABUS) trailing twelve-month net income is $161M as of 2025. Earnings grew +55.3% year-over-year.
Is ABUS profitable?
Yes, ABUS is profitable with a TTM net income of $161M and a net profit margin of -237.9%.
What is ABUS's earnings growth rate?
ABUS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1998 to 2025.
What are ABUS's profit margins?
Arbutus Biopharma Corporation net profit margin is -237.9%, operating margin is -192.1%, and gross margin is +97.4%. Below-average margins reflect competitive or cost pressures. Return on Equity is -38.5%.
Is ABUS growing earnings?
Yes, ABUS earnings are accelerating — EPS growth of +55.3% exceeds the 5-year CAGR of N/A. TTM net income reached $161M. Earnings momentum is strengthening.
What was ABUS's best earnings year?
Arbutus Biopharma Corporation's highest annual net income on record is $30M, achieved in fiscal year 2012. Earnings history on this page spans 1998 to 2025 and includes all annual and quarterly figures.
What were ABUS's earnings last quarter?
ABUS's most recent reported quarter was Q1 2026. Net income was $170M with diluted EPS of $0.87. For a full breakdown of all quarters, see the quarterly earnings table on this page.